Objective Programmed death 1 and its ligand 1 (PD-1/PD-L1) immunotherapy is promising for late-stage lung cancer treatment, however, the response rate needs to be improved. Gut microbiota plays a crucial role in immunotherapy sensitisation and Panax ginseng has been shown to possess immunomodulatory potential. In this study, we aimed to investigate whether the combination treatment of ginseng polysaccharides (GPs) and αPD-1 monoclonal antibody (mAb) could sensitise the response by modulating gut microbiota.
Design Syngeneic mouse models were administered GPs and αPD-1 mAb, the sensitising antitumour effects of the combination therapy on gut microbiota were assessed by faecal microbiota transplantation (FMT) and 16S PacBio single-molecule real-time (SMRT) sequencing. To assess the immune-related metabolites, metabolomics analysis of the plasma samples was performed.
Results We found GPs increased the antitumour response to αPD-1 mAb by increasing the microbial metabolites valeric acid and decreasing L-kynurenine, as well as the ratio of Kyn/Trp, which contributed to the suppression of regulatory T cells and induction of Teff cells after combination treatment. Besides, the microbial analysis indicated that the abundance of Parabacteroides distasonis and Bacteroides vulgatus was higher in responders to anti-PD-1 blockade than non-responders in the clinic. Furthermore, the combination therapy sensitised the response to PD-1 inhibitor in the mice receiving microbes by FMT from six non-responders by reshaping the gut microbiota from non-responders towards that of responders.
Conclusion Our results demonstrate that GPs combined with αPD-1 mAb may be a new strategy to sensitise non-small cell lung cancer patients to anti-PD-1 immunotherapy. The gut microbiota can be used as a novel biomarker to predict the response to anti-PD-1 immunotherapy.
- drug resistance
- cancer immunobiology
Data availability statement
Data are available on reasonable request. All data relevant to the study are included in the article or uploaded as online supplemental information.
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Significance of this study
What is already known on this subject?
The gut microbiota plays a crucial role in shaping the systemic immune system and has a major influence on the effectiveness of anticancer immunotherapy targeting the CTLA-4 and programmed death 1 and its ligand 1 (PD-1/PD-L1) pathways in both preclinical tumour models and patients with cancer.
The response rate of non-small cell lung cancer (NSCLC) patients to anti-PD-1 immunotherapy is less than 25%, dietary supplements may influence the gut microbiome and the response to anti-PD-1 immunotherapy.
Ginseng polysaccharides (GPs), one of the most abundant components of Panax ginseng, have an important influence on immunomodulation and antitumour effects.
Significance of this study
What are the new findings?
GPs potentiated the antitumour effect of an αPD-1 monoclonal antibody (mAb) in Lewis lung cancer-bearing mice.
Combination therapy with GPs and an αPD-1 mAb increased the activated CD8+ T cell population and reduced the Foxp3+ regulatory T cell population in the periphery, consistent with a decrease in the kynurenine/tryptophan ratio.
NSCLC responders and non-responders to pembrolizumab exhibited distinct gut microbiota diversity as detected by 16S PacBio SMRT sequencing, and two differentially abundant species, Parabacteroides distasonis and Bacteroides vulgatus were found.
Combination therapy with GPs and αPD-1 mAb reshaped the composition of the gut microbiota from non-responders towards that of the responders, which reinstated the response to the αPD-1 mAb in mice transplanted with PD-1 non-responder faecal samples.
How might it impact on clinical practice in the foreseeable future?
Gut microbiota status, such as alpha diversity, can be used as a biomarker to predict the response to anti-PD-1 immunotherapy in NSCLC patients.
GPs represent a novel class of prebiotics to enhance the response to anti-PD-1 immunotherapy in NSCLC patients.
P. distasonis and B. vulgatus can be used as adjuvants for anti-PD-1 immunotherapy.
Lung cancer has the highest morbidity and mortality rate worldwide.1 Approximately 80%–85% of all lung cancers are non-small cell lung cancers (NSCLCs). Inhibitors of programmed death 1 (PD-1) and its ligand PD-L1 are effective therapies for metastatic NSCLC lacking sensitising EGFR or ALK mutations.2–6 However, even though these biomarkers were used as the gold standard, the response rate (<25%) is still unsatisfactory, even leading to hyperprogressive disease (HPD).7 8 Hence, there remains a need for more effective first-line treatments for the majority of patients with advanced NSCLC and for predictive biomarkers to identify patients who may benefit from new therapies.9 Extensive research has been carried out identifying new combinations of PD-1/PD- L1 pathway inhibitors with other treatments or drugs with immunomodulatory effects which may enhance antitumour response.10 11 Recently, gut microbiota has fuelled great enthusiasm in cancer immunotherapy. Such as Bacteroides fragilis, Bacteroides thetaiotaomicron, Bifidobacterium, Akkermansia muciniphila and Faecalibacterium spp. have been shown to have favourable responses to cancer immunotherapy in both preclinical tumour models and patients with cancer.12–15 Strategies to modulate gut microbiota have thus been proposed to treat patients with cancer and act as novel response prediction biomarkers.
Panax ginseng has been widely used in Asia for thousands of years, not only as a medicine but also as a dietary supplement. The long-term administration of ginseng extracts has been shown to modulate the rat gut microbiota by increasing the abundance of Bifidobacterium, Allobaculum, Lactobacillus, Clostridium and Parasutterella.16 Quan et al reported that the whole extract of ginseng specifically increases the abundance of Enterococcus faecalis, which contributes to the antiobesity effect of its long-chain fatty acid metabolite myristoleic acid.17 Ginseng contains many active components, including ginsenosides, essential oils, peptidoglycans, polysaccharides, nitrogen-containing compounds, fatty acids and phenolic compounds.18 Among these components, ginseng polysaccharides (GPs) have been demonstrated to be responsible for the immunomodulatory functions, such as the activation of macrophages, T cells and natural killer cells. Moreover, GPs improve intestinal metabolism and modulate the gut microbiota and particularly enhance the growth of Lactobacillus spp. and Bacteroides spp., two major species of bacteria that metabolise ginsenosides.19 20 Nevertheless, the therapeutic potential of GPs has not been well explored in cancer immunotherapy. The main goal of our present study was to define the synergistic antitumour effect of GPs and investigate whether the potential effect is related to gut microbiota modulation and its associated treatment mechanisms.
The 8–12 weeks old C57BL/6J mice and humanised PD-1 knock-in (HuPD-1) mice were reared in independently vented cages at the animal facility of the State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology.
Approximately 5×105 Lewis lung cancer (LLC) cells and 5×104 B16-F10 cells were subcutaneously inoculated into the right flanks of mice. A total of 24 mice from different litters were equally divided into four groups: Vehicle (treated with PBS), αPD-1 monoclonal antibody (mAb) (250 µg/mouse, clone: RMP1-14, Bio X Cell), GPs (200 mg/kg) and GPs plus αPD-1 mAb group. Daily oral treatment with GPs was administrated after tumour inoculation and injection of αPD-1 mAb 5 times at 3-day intervals on day 9 when tumour volumes were approximately 50 mm3. Tumour volumes and body weights were measured every 3 days.
Antibodies and flow cytometry
At the endpoint of the experiment, the blood, spleen and tumours were harvested for flow cytometry analysis. Lamina propria mononuclear cells (LPMCs) were isolated using a LP dissociation kit (Miltenyi Biotec, Germany) according to the manufacturer’s instructions. Initially, the intraepithelial lymphocytes (IELs) were disrupted from the mucosa by shaking the tissue in a predigestion solution. Then, the LP tissue was further treated enzymatically and mechanically dissociated into a single-cell suspension containing LPMCs by using a gentle MACS dissociator.
For FACS analysis, single-cell suspensions were stained with the following antibodies: PerCP anti-mouse CD45, APC anti-mouse CD3, FITC anti-mouse CD4, and PE/Cy7 anti-mouse CD8 (Biolegend, clone 30-F11; clone 17A2, clone RM4-5, and clone 53–6.7, respectively, USA). For intracellular staining, cells were stimulated for 4–6 hour at 37°C with PMA (50 ng/mL), ionomycin (1 µg/mL) and BD Golgi STOPT. After being fixed and permeabilised, the cells were stained with APC/Cy7 antimouse interferon (IFN)-γ, PE/Dazzle 594 tumour necrosis factor (TNF)-α, PE antimouse granzyme B (GZMB), PE antimouse FoxP3, PerCP/Cy5.5 antimouse ROR-γt and PE anti-mouse interleukin-17A (Biolegend, clone XMG1.2, clone 506346, clone: 259D, clone MF-14, clone Q31-378, and clone TC11-18H10.1, respectively, USA). Flow cytometry analysis was performed using a FACSArial III flow cytometer (BD, USA). Data were analysed using FlowJo software (V.10.4, FlowJo, USA).
Metabolomic profiling of short-chain fatty acids and tryptophan in the plasma
The mouse blood samples were centrifuged at 3000 rpm for 15 min, and the supernatants were collected. The samples were then derivatised and analysed using ultraperformance liquid chromatography-mass spectrometry (UPLC-MS). Short-chain fatty acids (SCFAs), L-kynurenine, and L-tryptophan in the plasma were determined by following a modified protocol as previously described.21 22
Histopathological scoring and immunohistochemical staining
Tumour tissues and colons were dissected and partially embedded in 4% PFA for 48 hours. Paraffin-embedded tissue sections (5 µm) were stained with H&E for morphological examination. Immunohistochemical staining (IHC) was performed to evaluate the expression of CD4, CD8, IFN-γ, TNF-α, GZMB and IDO using immunohistochemistry kits (K8002; Dako, Glostrup, Denmark) according to the manufacturer’s protocol. Slides were scanned and observed under a Leica optical microscope (Leica Biosystems Imaging, USA).
Fecal microbiota transfer experiment
Faecal pellets from six NR were homogenised in 10 mL of sterile saline. Then, 200 µL of the suspension was transferred by oral gavage into each germ-free (GF) mouse (6–8 weeks old). Besides, another 100 μL was applied to the fur of each animal. GF mice were gavaged with faecal samples 3 times for 2 weeks. GF mice were maintained in a gnotobiotic isolator with irradiated food and autoclaved water at the Third Army Medical University (Chongqing, China) and the First Affiliated Hospital, Sun Yat-Sen University. Two weeks after faecal microbiota transplantation (FMT), tumour cells were inoculated, and the mice were treated with GPs and/or αPD-1 mAb as mentioned above.
RNA-sequencing of IELs
IELs were isolated as described previously with slight modification.23 Total RNA was extracted as instruction of RNeasy Plus Micro Kit (Qiagen, Germany). The detailed sequencing and differential expression analysis methods are described in online supplemental methods.
Fecal DNA extraction and 16S rRNA sequencing
Total genomic DNA of patients and mouse faecal samples were extracted using QIAamp PowerFecal DNA kits (Qiagen, Hilden, Germany) or Shoreline Complete StrainID Kit (Shoreline Biome, USA), respectively, according to the manufacturer’s instructions. The DNA concentration and purity were monitored on 1% agarose gels. Amplicon libraries were created using PacBio SMRTbell Express Template Prep Kit V.3.0 (PacBio) and sequenced on a PacBio Sequel System at Macau University of Science and Technology according to the manufacturer’s recommendation. SBanalyzer V.3.0 (Shoreline Biome) was used to assign taxonomic identification to all reads mapped to Athena database.24 QIIME 2 was used for further analysis.
All data are expressed as the mean±SEM The differences between groups were analysed by two-way analysis of variance (ANOVA) or one-way ANOVA. The critical p value was set to 0.05 for significant differences. Statistical analysis was performed by GraphPad Prism V.8.0.2 (San Diego, California, USA). A value of p<0.05 was considered statistically significant.
Combination therapy sensitises the antitumour effect of αPD-1 mAb in tumour-bearing mouse models
To investigate whether GPs can enhance the antitumour effect of αPD-1 mAb, we first evaluated tumour growth and progression in C57 BL/6J mice-bearing LLC. GPs oral gavage and αPD-1 mAb injection began to be administered to mice on days 0 and 9 post-tumour inoculation, respectively (figure 1A). The antitumour effect was initially evaluated by tumour volume and tumour weight (figure 1B,C). After combination treatment, the conventional LLC-bearing mice exhibited an increased response to αPD-1 mAb and reduced tumour progression (online supplemental figure 1A). On day 24, the combination treatment group exhibited 75.2% and 65.1% tumour growth suppression compared with the Vehicle and αPD-1mAb treatment alone group, respectively. Correspondingly, the survival of mice was significantly prolonged (figure 1D). These results indicate that combination treatment improves the antitumour effect of αPD-1 mAb in LLC-bearing mice. We also observed this potentiated antitumour effect in HuPD-1 mice with LLC cells (figure 1E,F) and B16-F10 tumour-bearing mice (online supplemental figure 1B,C).
In vivo antitumour effect of the combination treatment is associated with increased immunity
To determine the effects of the combination therapy on the immune system, we analysed the immunological changes in the peripheral blood, spleen and tumour tissues using flow cytometry. We observed that CD8+/CD4+ ratio in the combinational group increased in both peripheral (blood and spleen tissues) and tumour tissues when compared with αPD-1 mAb alone group (figure 2A). The production of functional cytokines, IFN-γ, TNF-α andGZMB among CD8+ T cells also increased both in peripheral and tumour tissues (figure 2B–D, (online supplemental figure 2), indicating the beneficial effect of the drug combination. Meanwhile, we also observed the downregulation of FoxP3+ regulatory T (Treg) cells in peripheral and tumour tissues (figure 2E). And the IHC profiles got consistent results in tumour tissues (figure 2F–K). These results indicated that combination treatment may take effect by activating CD8+ T cells and suppressing the function of Tregs.
Regulatory T cells (Tregs) are major players in the immunosuppressive tumour microenvironment, which is frequently associated with poor prognosis and survival.25 Clinical studies have identified a group of patients who may experience increased rapid cancer HPD risk after anti-PD-1 treatment due to the increased proliferation of FoxP3+ Treg cells, hindering the application of immunotherapy.26 27 In our study, GPs combined with αPD-1 mAb reduced the proportion of FoxP3+ Tregs both in the periphery and tumour, which may contribute to preventing HPD. Altogether, these data indicate the enhanced antitumour immunity effect of combination treatment.
Combination treatment prevents gut microbiota dysbiosis
To investigate whether gut microbiota is altered by oral GPs administration, we performed 16S PicBio SMRT sequencing on faecal samples from all treatment groups. After combination treatment, the microbial composition was changed and the abundance of Muribaculum was significantly increased compared with αPD-1 mAb alone group (figure 3A,B). We also observed the increase of Muribaculaceae when compared GP and Vehicle group (online supplemental figure 3), which indicated that GPs may have the potential to enrich the abundance of Muribaculaceae. To further elucidate the causal relationship between the gut microbiota and the antitumour effects, we evaluated the tumour growth in LLC-bearing mice treated with antibiotics and found antibiotic treatment compromised the antitumour efficacy (figure 3C,D). In terms of the maintenance of intestinal immunity, histopathological evaluation of the colon revealed that the combination treatment could reduce the infiltration of inflammatory cells in the colon (figure 3E,F).
IELs play a vital role in maintaining barrier function and decreasing susceptibility to infection and immunopathology. To investigate whether the combination treatment impacts IELs, we adopted RNA-sequencing to examine the transcriptome changes of IELs in the small intestine. Compared with that in the αPD-1 mAb alone group, the expression of intraepithelial protection genes (CLCA3, Zg16, Pla2g10, Agr2, Guca2a and Tff3),28–30 metabolism-related genes (Dgat2 and Ces2a)31 32 and S100A6 was significantly upregulated in the combination treatment group. Conversely, the expression of immunoglobulin variable region heavy chain genes (Ighv1-64, Ighv6-6, Ighv5-4, Ighv1-55, Ighv1-50 and Ighv1-26), immunoglobulin variable region light chain genes (Iglv2), immunoglobulin kappa variable genes (Igkv4-68), Lrrk2, Camsap2, Myo5a, Bmf, Slc29a3, and Mios was downregulated in the IELs from mice treated with combination therapy (figure 3G). Gene ontology (GO) analysis revealed that these differentially expressed genes were mainly associated with the lysosome, secretory granule and energy metabolism, which can protect the integrity of the gut barrier (figure 3H). When compared with GP alone group, we observed that the immune response-rated genes were upregulated in the combination group (figure 3I,J).
RORγt+ Treg cells can be induced in the gut in response to microbial stimuli.33 The balance between RORγt+ Treg cells and Th17 cells can help to maintain gut homeostasis. To observe the protective effect on the intestinal tract, we examined the proportions of RORγt+ Treg cells and Th17 cells in the LP of the colon. As expected, increased proportions of RORγt+ Treg cells and reduced proportions of Th17 cells were found in the combination treatment group (figure 3K,L).
Combination treatment increases SCFA abundance and dysregulates indoleamine 2,3-dioxygenase (IDO) activity
RORγt+ Tregs are induced by microbiota through SCFAs.33 SCFAs are crucial metabolites that can serve as an energy source and prevent intestinal epithelial cells and lymphocytes from undergoing autophagy due to nutrient starvation.34 SCFAs in the host are not limited to the gut; they can also disseminate into the blood and thus communicate with multiple cells in target tissues in a G-protein-coupled receptors (GPCR)-dependent manner or by suppressing histone deacetylases (HDAC) epigenetic activity.35 Thus, SCFAs may mediate the contribution of the microbiota to cancer immunity. To investigate the effect of SCFAs, we detected SCFAs (acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid, isovaleric acid and hexanoic acid) production in the plasma of animals using ultra-performanceliquid chromatography-mass spectrometry (UPLC/MS). Interestingly, we found that the abundance of all the SCFAs increased after treatment with αPD-1 mAb except for acetic acid; notably, the abundance of valeric acid was significantly increased in the combination treatment group compared with αPD-1 mAb alone group (figure 4A–G).
Other than SCFAs, we also measured 52 amino acids and fatty acid metabolites changes (online supplemental figure 4A). We observed tryptophan metabolism contributes most among these metabolites with a marked decrease of L-kynurenine and the ratio of Kyn/Trp (expressed as IDO activity) but not L-tryptophan in the combination treatment group compared with the αPD-1 mAb alone group (online supplemental file 4A–D, Figure 4H–J). The results indicated that combination treatment may be associated with IDO activity. To further investigate the IDO activity in tumour tissues, we performed IHC staining and found the expression of IDO in the combination group was downregulated (figure 4K). To determine the effect of GPs on tryptophan metabolism in gut microbes, we meta-fermented human faecal samples with GPs by an in vitro batch fermentation system. Interestingly, we found that GPs markedly increased the production of L-tryptophan and reduced the production of L-kynurenine, as well as the kynurenine/tryptophan ratio both under aerobic and anaerobic fermentation conditions (online supplemental table 1), suggesting that GPs could influence tryptophan metabolism through gut microbes.
Distinct gut microbiota composition is present in pembrolizumab-treated NSCLC responders and non-responders
Sixteen Chinese patients with NSCLC were enrolled and treated with anti-PD-1 blockade. Ten of these patients were classified as responders (Rs), and six as non-NRs (NRs) assessed by a physician at Kiang Wu Hospital in Macau. The clinical-pathological features of these patients are listed in online supplemental table 2). All patients were followed up over 30 months, and their response status was monitored with CT scans (online supplemental figure 5A–C).
To investigate whether the composition of the gut microbiome was associated with anti-PD-1 immunotherapy, baseline faecal samples were collected and subjected to 16S PacBio SMRT sequencing. The alpha diversity of the gut microbiome suggested that the richness and evenness of the Rs were higher than those of the NRs (figure 5A). At the species level, we observed that the relative abundance of Bacteroides vulgatus accounts for the top of the list in Rs, as well as an overrepresentation of three gut microbes: Parabacteroides distasonis (p=0.04), bacterium LF-3 (p=0.02) and Sutterella wadsworthensis HGA0223 (p=0.09; figure 5B–G, (online supplemental file 5D–G). Interestingly, the abundance of these bacteria was increased in patients who had better response and survival rates.
GPs reinstate the response to αPD-1 mAb treatment in LLC-bearing mice transplanted with feces from non-Rs
In our initial study, we found that GPs potentiated the antitumour effect of αPD-1 mAb in LLC-bearing mice. Whether GPs could reverse the response to αPD-1 mAb treatment in humans remains unknown; therefore, we designed an FMT experiment to investigate it. Faecal microbiota from the six NRs was transferred into GF mice. When colonised, the mice were inoculated with LLC tumour cells. Then, mice were treated with the same mouse protocol as previously used (figure 6A). As expected, similarly to the NRs, we found that mice were resistant to αPD-1 mAb treatment. Interestingly, when mice were treated with GPs plus αPD-1 mAb, the response was reinstated. The combination treatment significantly delayed tumour growth (figure 6B). Flow cytometry analysis and IHC profiles suggested that the ratio of CD8+/CD4+ T cells and the production of IFN-γ, TNF-α and GZMB in CD8+ T cells were increased both in the blood and tumours (figure 6C–F,H–M). We also observed fewer Treg cells in the combination group, which was associated with improved treatment efficacy (figure 6G). Meanwhile, we determined the content of tryptophan and kynurenine in mice plasma and found Kyn/Trp ratio decreased after combination treatment (figure 6J). Consistently, we also observed a lower IDO expression in tumour tissues after combination treatment (figure 6K,L). Collectively, these data revealed that GPs can sensitise the response to αPD-1 mAb in LLC-bearing mice.
Likewise, we examined whether combination treatment could modulate the gut microbiota in LLC tumour-bearing mice transplanted with gut microbiota from NRs. Excitingly, we found in combination group, the abundance of Bacteroides, especially B. vulgatus and P. distasonis were significantly increased when compared with αPD-1 mAb and Vehicle group, respectively (figure 6M,O, (online supplemental file 6A–C). No bacteria contamination during the GF cultivation condition was confirmed by time-course 16S rRNA sequencing (online supplemental file 7A–B). These results indicated that the combination treatment may reshape gut microbiota from NRs towards that of Rs to sensitise the response to αPD-1 mAb treatment.
PD-1 inhibitors are effective cancer immunotherapy in various types of cancer. However, the response rate needs to be largely improved. Accumulating numbers of clinical trials using combination therapies are currently in progress looking for enhanced sensitisation methods. GPs have also previously been reported to be an adjuvant drug for immunomodulation. Zhou et al demonstrated that GPs reinstate gut homeostasis, particularly by enhancing the growth of two major metabolic bacteria, Lactobacillus spp and Bacteroides spp., which may reverse overfatigue and acute cold stress phenotypes by enhancing host immune function.36 Bacteroides spp. have a protective effect on gastrointestinal toxicity during CTLA-4 mAb treatment.13 In the present study, we first observed that GPs combined with αPD-1 mAb could increase the SCFA-producing bacteria, Muribaculum to sensitise the antitumour effect of αPD-1 mAb in the LLC tumour-bearing mice. Muribaculum was the first genus found in Muribaculaceae which was also named Bacteroidales S24-7. S24-7 was the predominant Bacteroidetes member in mice and was reported to be associated with better response to immunotherapy.37 Whereas, in human subjects, the family Bacteroidaceae and the genus Bacteroides were the predominant Bacteroidetes members.38 Besides, the difficulty to the culture of S24-7 limited further research.39 Our present study overscores the antitumour effect was attributable to the enhanced CD8+ functional T cells and the downregulation of Treg cells by altering the gut microbiome.
Microbial metabolites intermediate the communication between microbiota and immune cells. SCFAs result from polysaccharide degradation by microbes. Whether SCFAs impact host physiology after treatment with αPD-1 mAb is still unclear. Nomura et al observed that the abundance of faecal SCFAs in solid cancer patients treated with nivolumab was higher in R than NR. These results suggest that increased SCFAs point to longer progression-free survival time.40 In this study, we also observed that all the SCFAs including propionate, butyrate, isobutyrate, valerate, isovalerate and hexanoate, increased after treatment with αPD-1 mAb. In particular, valerate, which is commonly low in the plasma, was increased significantly after cotreatment with GPs and αPD-1 mAb compared with treatment with αPD-1 mAb alone. However, relatively little research has focused on valerate. We reason valerate may serve as HDAC inhibitor to delay tumour progression and upregulate immune response.41 42 Further study will address whether valerate is potentially therapeutically useful for the αPD-1 mAb response and whether the microbiota is associated with this effect.
IDO activity has been proposed to be a possible mechanism of resistance to anti-PD-1 treatment, and several combination therapies have been launched into clinical trials.43–45 Although the IDO-1 inhibitor, epacadostat (ECHO-301/KEYNOTE-252 trial) in combination with pembrolizumab, although in melanoma patients recently for many reasons,46 IDO-1 is still a promising immune checkpoint which is associated with the attenuation of Treg cell activation.47 The higher ratio of Kyn/Trp leads to the induction of Treg production and the suppression of Teff cell production, as well as poor survival.48 49 A previous study revealed that ginsenosides could decrease the concentration of kynurenine and the Kyn/Trp ratio in mouse plasma,50 but whether GPs exhibit a similar effect is unknown. We in vitro fermented human faecal samples from healthy donors with GPs and found an increase in tryptophan and a reduction in kynurenine levels under both aerobic and anaerobic conditions. In addition, compared with αPD-1 mAb treatment alone, combination treatment led to a reduced Kyn/Trp ratio by reducing kynurenine but not tryptophan in mice. This result is consistent with the enhanced αPD-1 mAb response and increased survival time. Additionally, the peripheral Treg population decreased in response to the reduction in kynurenine. We also observed the decreased IDO activity in GF mice transferred microbiota from NRs. Collectively, GPs may improve the response to PD-1 inhibitor via decreasing IDO activity.
Previous studies show different groups got different microbes associated with the response to PD-1 inhibitor, which mainly concentrated on western people. Whether it is related to geographical differences remains to be seen. Jin et al enrolled 37 Chinese advanced NSCLC patients receiving nivolumab and patients using second-generation sequencing, found an enrichment of Alistipes putredinis, Bifidobacterium longum and Prevotella copri in responding patients, whereas Ruminococcus_unclassified was enriched in non-responding patients.51 Here, we first examined the influence of the gut microbiota on the response of Asian patients with NSCLC to pembrolizumab using 16S PacBio SMRT sequencing. The results revealed enrichment of B. vulgatus and P. distasonis in Rs. B. vulgatus and P. distasonis are two species of commensal healthy bacteria.52 P. distasonis has been shown to enhance immune checkpoint inhibitor-mediated anticancer immunity by inducing the production of IFNγ+CD8+ T cells.53 54 The genus Bacteroides enhance the antitumour effect and alleviate the gastrointestinal toxicity in melanoma patients treated with CTLA-4 blockade.13
Based on these studies, we investigated whether GPs in combination with αPD-1 mAb could reverse the response state. We transferred stool from 6 NRs to GF mice to study the effect of the gut microbiota on LLC-bearing mice. Excitingly, we found the abundance of B. vulgatus and P. distasonis were significantly increased after combination treatment compared with αPD-1 mAb or Vehicle group, respectively. This finding suggests that GPs sensitise the outcome of αPD-1 mAb therapy in recipient mice receiving faecal microbiota from NR donors by reshaping the gut microbiome from NRs towards that of Rs. Our GPs are commercially available as a dietary supplement, and we believe that our study can accelerate the clinical translation of GPs. Next, whether B. vulgatus and P. distasonis are the key orchestrators of the resistance to PD-1 inhibitors will be further investigated.
In summary, we revealed that GPs potentiate the antitumour effect of αPD-1 mAb by enhancing CD8+ T cell function and reducing the suppressive effect of Tregs, which might be addressed by reshaping the gut microbiota and tryptophan metabolism. Additionally, we found that P. distasonis and B. vulgatus are over-represented among Chinese NSCLC Rs. Furthermore, the combination treatment increased the abundance of B. vulgatus and P. distasonis and reinstated the response to αPD-1 mAb in GF mice colonised with FMT from NR patients. Overall, our novel findings are summarised and illustrated in figure 7A,B. Our data indicate that GPs can be used as a dietary supplement for NSCLC patients to improve immunotherapy efficacy.
Data availability statement
Data are available on reasonable request. All data relevant to the study are included in the article or uploaded as online supplemental information.
Patient consent for publication
This study was conducted with the approval of the Kiang Wu Hospital, Macau. Ethics approval of animal studies were provided by Macau University of Science and Technology, the Third Army Medical University and the First Affiliated Hospital, Sun Yat-Sen University. All experiments were performed in compliance with institutional animal care guidelines and protocols approved by the committee.
We would like to thank the Department of Pathology, University Hospital, Macau University of Science and Technology for the preparation of paraffin sections. We also appreciated Army Medical University for the supply of germ-free mice and Biocytogen for the supply of HuPD-1 mice.
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
JH, DL and YW contributed equally.
Contributors EL-HL, YC, HW, JH and ZJ designed the study. JH, JY, ZJ, JL, XF, YZ, YX, HL, WW, YF, JL, AS, JC, JL, MY, LW, LL and RL performed the experiments. EL-HL, YC, DL, YW, WH, IK, HL, XY, YX, J-LW, QW and PY analysed the data. ZJ and XF carried out the FACS analysis. EL-HL, JH, YC, HW, ZJ and LL wrote the manuscript. All authors reviewed and approved the manuscript.
Funding This work was supported by Macao Science and Technology Development Fund (Project no: 0096/2018/A3, 001/2020/ALC), and the NSFC overseas and Hong Kong and Macao Scholars Cooperative Research Fund Project (Project no: 81828013).
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.